Clinical  ||| S:0 E:9 ||| JJ
analysis  ||| S:9 E:18 ||| NN
of  ||| S:18 E:21 ||| IN
nervous  ||| S:21 E:29 ||| JJ
system  ||| S:29 E:36 ||| NN
involvement  ||| S:36 E:48 ||| NN
in  ||| S:48 E:51 ||| IN
ANCA-associated  ||| S:51 E:67 ||| JJ
systemic  ||| S:67 E:76 ||| JJ
vasculitides  ||| S:76 E:89 ||| NN
To  ||| S:89 E:92 ||| TO
assess  ||| S:92 E:99 ||| VB
the  ||| S:99 E:103 ||| DT
clinical  ||| S:103 E:112 ||| JJ
features  ||| S:112 E:121 ||| NNS
of  ||| S:121 E:124 ||| IN
nervous  ||| S:124 E:132 ||| JJ
system  ||| S:132 E:139 ||| NN
( ||| S:139 E:140 ||| -LRB-
NS ||| S:140 E:142 ||| NNP
)  ||| S:142 E:144 ||| -RRB-
involvement  ||| S:144 E:156 ||| NN
in  ||| S:156 E:159 ||| IN
patients  ||| S:159 E:168 ||| NNS
with  ||| S:168 E:173 ||| IN
ANCA-associated  ||| S:173 E:189 ||| JJ
vasculitides  ||| S:189 E:202 ||| NNS
( ||| S:202 E:203 ||| -LRB-
AAV ||| S:203 E:206 ||| NNP
) ||| S:206 E:207 ||| -RRB-
,  ||| S:207 E:209 ||| ,
including  ||| S:209 E:219 ||| VBG
microscopic  ||| S:219 E:231 ||| JJ
polyangiitis  ||| S:231 E:244 ||| NNS
( ||| S:244 E:245 ||| -LRB-
MPA ||| S:245 E:248 ||| NNP
) ||| S:248 E:249 ||| -RRB-
,  ||| S:249 E:251 ||| ,
Wegener ||| S:251 E:258 ||| NNP
's  ||| S:258 E:261 ||| POS
granulomatosis  ||| S:261 E:276 ||| NN
( ||| S:276 E:277 ||| -LRB-
WG ||| S:277 E:279 ||| NNP
) ||| S:279 E:280 ||| -RRB-
,  ||| S:280 E:282 ||| ,
and  ||| S:282 E:286 ||| CC
Churg-Strauss  ||| S:286 E:300 ||| JJ
syndrome  ||| S:300 E:309 ||| NN
( ||| S:309 E:310 ||| -LRB-
CSS ||| S:310 E:313 ||| NNP
) ||| S:313 E:314 ||| -RRB-
.  ||| S:314 E:316 ||| .
One  ||| S:316 E:320 ||| CD
hundred  ||| S:320 E:328 ||| CD
and  ||| S:328 E:332 ||| CC
seventy-nine  ||| S:332 E:345 ||| JJ
patients  ||| S:345 E:354 ||| NNS
admitted  ||| S:354 E:363 ||| VBD
to  ||| S:363 E:366 ||| TO
Peking  ||| S:366 E:373 ||| NNP
Union  ||| S:373 E:379 ||| NNP
Medical  ||| S:379 E:387 ||| NNP
College  ||| S:387 E:395 ||| NNP
Hospital  ||| S:395 E:404 ||| NNP
from  ||| S:404 E:409 ||| IN
1995  ||| S:409 E:414 ||| CD
to  ||| S:414 E:417 ||| TO
2008 ||| S:417 E:421 ||| CD
,  ||| S:421 E:423 ||| ,
including  ||| S:423 E:433 ||| VBG
93  ||| S:433 E:436 ||| CD
cases  ||| S:436 E:442 ||| NNS
of  ||| S:442 E:445 ||| IN
MPA ||| S:445 E:448 ||| NNP
,  ||| S:448 E:450 ||| ,
61  ||| S:450 E:453 ||| CD
cases  ||| S:453 E:459 ||| NNS
of  ||| S:459 E:462 ||| IN
WG ||| S:462 E:464 ||| NNP
,  ||| S:464 E:466 ||| ,
and  ||| S:466 E:470 ||| CC
25  ||| S:470 E:473 ||| CD
cases  ||| S:473 E:479 ||| NNS
of  ||| S:479 E:482 ||| IN
CSS ||| S:482 E:485 ||| NNP
,  ||| S:485 E:487 ||| ,
were  ||| S:487 E:492 ||| VBD
enrolled  ||| S:492 E:501 ||| VBN
in  ||| S:501 E:504 ||| IN
this  ||| S:504 E:509 ||| DT
study ||| S:509 E:514 ||| NN
.  ||| S:514 E:516 ||| .
Medical  ||| S:516 E:524 ||| JJ
charts  ||| S:524 E:531 ||| NNS
including  ||| S:531 E:541 ||| VBG
demographic  ||| S:541 E:553 ||| JJ
data ||| S:553 E:557 ||| NNS
,  ||| S:557 E:559 ||| ,
clinical  ||| S:559 E:568 ||| JJ
features ||| S:568 E:576 ||| NNS
,  ||| S:576 E:578 ||| ,
laboratory  ||| S:578 E:589 ||| NN
findings ||| S:589 E:597 ||| NNS
,  ||| S:597 E:599 ||| ,
treatments  ||| S:599 E:610 ||| NNS
and  ||| S:610 E:614 ||| CC
outcomes  ||| S:614 E:623 ||| NNS
were  ||| S:623 E:628 ||| VBD
systematically  ||| S:628 E:643 ||| RB
reviewed ||| S:643 E:651 ||| VBN
.  ||| S:651 E:653 ||| .
NS  ||| S:653 E:656 ||| NNP
involvements  ||| S:656 E:669 ||| NN
were  ||| S:669 E:674 ||| VBD
observed  ||| S:674 E:683 ||| VBN
in  ||| S:683 E:686 ||| IN
36.6 ||| S:686 E:690 ||| CD
%  ||| S:690 E:692 ||| NN
of  ||| S:692 E:695 ||| IN
MPA ||| S:695 E:698 ||| NNP
,  ||| S:698 E:700 ||| ,
50.8 ||| S:700 E:704 ||| CD
%  ||| S:704 E:706 ||| NN
of  ||| S:706 E:709 ||| IN
WG ||| S:709 E:711 ||| NNP
,  ||| S:711 E:713 ||| ,
and  ||| S:713 E:717 ||| CC
76.0 ||| S:717 E:721 ||| CD
%  ||| S:721 E:723 ||| NN
of  ||| S:723 E:726 ||| IN
CSS  ||| S:726 E:730 ||| NNP
patients ||| S:730 E:738 ||| NNS
.  ||| S:738 E:740 ||| .
Peripheral  ||| S:740 E:751 ||| JJ
neuropathy  ||| S:751 E:762 ||| JJ
predominated  ||| S:762 E:775 ||| NN
in  ||| S:775 E:778 ||| IN
each  ||| S:778 E:783 ||| DT
type  ||| S:783 E:788 ||| NN
of  ||| S:788 E:791 ||| IN
AAV ||| S:791 E:794 ||| NNP
.  ||| S:794 E:796 ||| .
In  ||| S:796 E:799 ||| IN
CSS  ||| S:799 E:803 ||| NNP
and  ||| S:803 E:807 ||| CC
MPA ||| S:807 E:810 ||| NNP
,  ||| S:810 E:812 ||| ,
the  ||| S:812 E:816 ||| DT
majority  ||| S:816 E:825 ||| NN
was  ||| S:825 E:829 ||| VBD
mononeuritis  ||| S:829 E:842 ||| JJ
multiplex  ||| S:842 E:852 ||| NN
and  ||| S:852 E:856 ||| CC
distal  ||| S:856 E:863 ||| JJ
symmetrical  ||| S:863 E:875 ||| JJ
polyneuropathy ||| S:875 E:889 ||| NN
,  ||| S:889 E:891 ||| ,
whereas ||| S:891 E:898 ||| NN
,  ||| S:898 E:900 ||| ,
differently ||| S:900 E:911 ||| RB
,  ||| S:911 E:913 ||| ,
64.5 ||| S:913 E:917 ||| CD
%  ||| S:917 E:919 ||| NN
of  ||| S:919 E:922 ||| IN
WG  ||| S:922 E:925 ||| NNP
patients  ||| S:925 E:934 ||| NNS
with  ||| S:934 E:939 ||| IN
NS  ||| S:939 E:942 ||| NNP
involvement  ||| S:942 E:954 ||| NN
had  ||| S:954 E:958 ||| VBD
cranial  ||| S:958 E:966 ||| JJ
neuropathy ||| S:966 E:976 ||| NN
.  ||| S:976 E:978 ||| .
Central  ||| S:978 E:986 ||| JJ
nervous  ||| S:986 E:994 ||| JJ
system  ||| S:994 E:1001 ||| NN
( ||| S:1001 E:1002 ||| -LRB-
CNS ||| S:1002 E:1005 ||| NNP
)  ||| S:1005 E:1007 ||| -RRB-
involvement  ||| S:1007 E:1019 ||| NN
accounted  ||| S:1019 E:1029 ||| VBD
for  ||| S:1029 E:1033 ||| IN
21.1 ||| S:1033 E:1037 ||| CD
% ||| S:1037 E:1038 ||| NN
,  ||| S:1038 E:1040 ||| ,
29.4 ||| S:1040 E:1044 ||| CD
% ||| S:1044 E:1045 ||| NN
,  ||| S:1045 E:1047 ||| ,
and  ||| S:1047 E:1051 ||| CC
32.3 ||| S:1051 E:1055 ||| CD
%  ||| S:1055 E:1057 ||| NN
of  ||| S:1057 E:1060 ||| IN
neuropathy  ||| S:1060 E:1071 ||| VBG
respectively  ||| S:1071 E:1084 ||| RB
in  ||| S:1084 E:1087 ||| IN
CSS ||| S:1087 E:1090 ||| NNP
,  ||| S:1090 E:1092 ||| ,
MPA  ||| S:1092 E:1096 ||| NNP
and  ||| S:1096 E:1100 ||| CC
WG  ||| S:1100 E:1103 ||| NNP
patients ||| S:1103 E:1111 ||| NNS
,  ||| S:1111 E:1113 ||| ,
including  ||| S:1113 E:1123 ||| VBG
arachnoid  ||| S:1123 E:1133 ||| JJ
hemorrhage ||| S:1133 E:1143 ||| NN
,  ||| S:1143 E:1145 ||| ,
cerebrovascular  ||| S:1145 E:1161 ||| JJ
neuro-pathy ||| S:1161 E:1172 ||| NN
,  ||| S:1172 E:1174 ||| ,
meningitis ||| S:1174 E:1184 ||| NN
,  ||| S:1184 E:1186 ||| ,
and  ||| S:1186 E:1190 ||| CC
diffuse  ||| S:1190 E:1198 ||| JJ
brain  ||| S:1198 E:1204 ||| NN
damage.  ||| S:1204 E:1212 ||| CD
157  ||| S:1212 E:1216 ||| CD
( ||| S:1216 E:1217 ||| -LRB-
87.7 ||| S:1217 E:1221 ||| CD
% ||| S:1221 E:1222 ||| NN
)  ||| S:1222 E:1224 ||| -RRB-
AAV  ||| S:1224 E:1228 ||| NNP
patients  ||| S:1228 E:1237 ||| NNS
responded  ||| S:1237 E:1247 ||| VBD
to  ||| S:1247 E:1250 ||| TO
treatment  ||| S:1250 E:1260 ||| NN
with  ||| S:1260 E:1265 ||| IN
high  ||| S:1265 E:1270 ||| JJ
dose  ||| S:1270 E:1275 ||| NN
of  ||| S:1275 E:1278 ||| IN
prednisone  ||| S:1278 E:1289 ||| NN
plus  ||| S:1289 E:1294 ||| CC
immunosuppressants ||| S:1294 E:1312 ||| NN
.  ||| S:1312 E:1314 ||| .
Thirteen  ||| S:1314 E:1323 ||| NNP
( ||| S:1323 E:1324 ||| -LRB-
14.0 ||| S:1324 E:1328 ||| NNP
% ||| S:1328 E:1329 ||| NN
)  ||| S:1329 E:1331 ||| -RRB-
MPA  ||| S:1331 E:1335 ||| NNP
and  ||| S:1335 E:1339 ||| CC
four  ||| S:1339 E:1344 ||| CD
( ||| S:1344 E:1345 ||| -LRB-
6.6 ||| S:1345 E:1348 ||| CD
% ||| S:1348 E:1349 ||| NN
)  ||| S:1349 E:1351 ||| -RRB-
WG  ||| S:1351 E:1354 ||| NNP
patients  ||| S:1354 E:1363 ||| NNS
died ||| S:1363 E:1367 ||| VBD
.  ||| S:1367 E:1369 ||| .
The  ||| S:1369 E:1373 ||| DT
leading  ||| S:1373 E:1381 ||| JJ
causes  ||| S:1381 E:1388 ||| NNS
of  ||| S:1388 E:1391 ||| IN
death  ||| S:1391 E:1397 ||| NN
were  ||| S:1397 E:1402 ||| VBD
diffuse  ||| S:1402 E:1410 ||| FW
alveolar  ||| S:1410 E:1419 ||| FW
hemorrhage  ||| S:1419 E:1430 ||| FW
( ||| S:1430 E:1431 ||| -LRB-
DAH ||| S:1431 E:1434 ||| NNP
)  ||| S:1434 E:1436 ||| -RRB-
( ||| S:1436 E:1437 ||| -LRB-
6 ||| S:1437 E:1438 ||| CD
,  ||| S:1438 E:1440 ||| ,
35.3 ||| S:1440 E:1444 ||| CD
% ||| S:1444 E:1445 ||| NN
)  ||| S:1445 E:1447 ||| -RRB-
and  ||| S:1447 E:1451 ||| CC
infection  ||| S:1451 E:1461 ||| NN
( ||| S:1461 E:1462 ||| -LRB-
6 ||| S:1462 E:1463 ||| CD
,  ||| S:1463 E:1465 ||| ,
35.3 ||| S:1465 E:1469 ||| CD
% ||| S:1469 E:1470 ||| NN
) ||| S:1470 E:1471 ||| -RRB-
.  ||| S:1471 E:1473 ||| .
No  ||| S:1473 E:1476 ||| DT
patient  ||| S:1476 E:1484 ||| NN
died  ||| S:1484 E:1489 ||| VBD
directly  ||| S:1489 E:1498 ||| RB
of  ||| S:1498 E:1501 ||| IN
neuropathy ||| S:1501 E:1511 ||| NN
.  ||| S:1511 E:1513 ||| .
NS  ||| S:1513 E:1516 ||| NNP
involvement  ||| S:1516 E:1528 ||| NN
was  ||| S:1528 E:1532 ||| VBD
common  ||| S:1532 E:1539 ||| JJ
in  ||| S:1539 E:1542 ||| IN
AAVs  ||| S:1542 E:1547 ||| JJ
and  ||| S:1547 E:1551 ||| CC
the  ||| S:1551 E:1555 ||| DT
characteristic  ||| S:1555 E:1570 ||| NN
of  ||| S:1570 E:1573 ||| IN
NS  ||| S:1573 E:1576 ||| NNP
involvement  ||| S:1576 E:1588 ||| NN
was  ||| S:1588 E:1592 ||| VBD
different  ||| S:1592 E:1602 ||| JJ
among  ||| S:1602 E:1608 ||| IN
MPA ||| S:1608 E:1611 ||| NNP
,  ||| S:1611 E:1613 ||| ,
WG  ||| S:1613 E:1616 ||| NNP
and  ||| S:1616 E:1620 ||| CC
CSS  ||| S:1620 E:1624 ||| NNP
patients ||| S:1624 E:1632 ||| NNS
.  ||| S:1632 E:1634 ||| .
DAH  ||| S:1634 E:1638 ||| NNP
and  ||| S:1638 E:1642 ||| CC
infection  ||| S:1642 E:1652 ||| NN
instead  ||| S:1652 E:1660 ||| RB
of  ||| S:1660 E:1663 ||| IN
NS  ||| S:1663 E:1666 ||| NNP
damage  ||| S:1666 E:1673 ||| NN
remained  ||| S:1673 E:1682 ||| VBD
the  ||| S:1682 E:1686 ||| DT
leading  ||| S:1686 E:1694 ||| JJ
causes  ||| S:1694 E:1701 ||| NNS
of  ||| S:1701 E:1704 ||| IN
death  ||| S:1704 E:1710 ||| NN
in  ||| S:1710 E:1713 ||| IN
AAVs ||| S:1713 E:1717 ||| JJ
.  ||| S:1717 E:1719 ||| .
